Aquestive Therapeutics Inc (NASDAQ: AQST) kicked off on Monday, up 8.01% from the previous trading day, before settling in for the closing price of $5.99. Over the past 52 weeks, AQST has traded in a range of $2.12-$7.55.
During the last 5-year period, the sales growth of Healthcare Sector giant was 27.90%. While this was happening, its average annual earnings per share was recorded -22.00%. With a float of $114.24 million, this company’s outstanding shares have now reached $121.66 million.
Aquestive Therapeutics Inc (AQST) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Aquestive Therapeutics Inc is 6.36%, while institutional ownership is 51.21%. The most recent insider transaction that took place on Nov 17 ’25, was worth 286,209. Before that another transaction happened on Oct 15 ’25, when Company’s Chief Operating Officer sold 67,575 for $7.01, making the entire transaction worth $473,701. This insider now owns 240,771 shares in total.
Aquestive Therapeutics Inc (AQST) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.16 earnings per share (EPS), lower than consensus estimate (set at -0.13) by -0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -22.00% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 28.81% during the next five years compared to 27.90% growth over the previous five years of trading.
Aquestive Therapeutics Inc (NASDAQ: AQST) Trading Performance Indicators
Take a look at Aquestive Therapeutics Inc’s (AQST) current performance indicators. Last quarter, stock had a quick ratio of 5.62. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 18.19.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.70, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.52 in one year’s time.
Technical Analysis of Aquestive Therapeutics Inc (AQST)
Looking closely at Aquestive Therapeutics Inc (NASDAQ: AQST), its last 5-days average volume was 2.12 million, which is a jump from its year-to-date volume of 2.05 million. As of the previous 9 days, the stock’s Stochastic %D was 68.57%.
During the past 100 days, Aquestive Therapeutics Inc’s (AQST) raw stochastic average was set at 72.02%, which indicates a significant decrease from 82.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.29 in the past 14 days, which was lower than the 0.34 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.19, while its 200-day Moving Average is $4.38. However, in the short run, Aquestive Therapeutics Inc’s stock first resistance to watch stands at $6.65. Second resistance stands at $6.84. The third major resistance level sits at $7.19. If the price goes on to break the first support level at $6.11, it is likely to go to the next support level at $5.76. Now, if the price goes above the second support level, the third support stands at $5.57.
Aquestive Therapeutics Inc (NASDAQ: AQST) Key Stats
The company with the Market Capitalisation of 789.36 million has total of 122,003K Shares Outstanding. Its annual sales at the moment are 57,560 K in contrast with the sum of -44,140 K annual income. Company’s last quarter sales were recorded 12,810 K and last quarter income was -15,450 K.
